Adial Pharmaceuticals announces it has been awarded a “key patent” combining the use of the company’s proprietary genetic diagnostic to detect select genotypes for genetically target treatment of alcohol use disorder, or AUD, and opioid use disorder, or OUD, with the company’s lead investigational new drug product AD04. “This patent marks another important milestone in our pursuit to provide tailored, more effective treatments for individuals grappling with AUD and OUD. By combining our novel genetic diagnostic with AD04, a potentially transformative therapy for those battling AUD and OUD, we aim to optimize therapeutic outcomes, ensuring that patients receive the most suitable treatment for their unique genetic profile,” stated Cary Claiborne, CEO of Adial Pharmaceuticals.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ADIL:
- Adial Pharmaceuticals Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
- Adial Pharmaceuticals Awarded Notice of Allowance for Key Patent Combining Use of the Company’s Proprietary Genetic Diagnostic with AD04 to Treat Alcohol and Drug Dependence
- Adial Pharmaceuticals Wins Frost & Sullivan’s 2023 North American Precision Medicine for Addiction Disorders Technology Innovation Leadership Award
- Biotech Alert: Searches spiking for these stocks today
- Adial Pharmaceuticals to Host a Virtual Key Opinion Leader Webinar to Discuss the Unmet Need in Alcohol Use Disorder